谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.
研究兴趣

论文共 49 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
MA06.05 A Phase II Study of Lorlatinib in Advanced ROS1+ NSCLC Pre-Treated with Crizotinib and Platinum-Based Chemotherapy
H. Chen, Y.-L. Wu, Z. Huang, L. Sun, X. Li, L. Chen, J. Li, Z. Zhu,W. Zhuang, K. Lu, Y. Zhang, K. Wang, Y. Chen,D. Huang, J. Zhao, Y. He, P. Zhang,X. Meng,Y. Du, Y. Guo
Journal of Thoracic Oncologyno. 10 (2024): S74
引用0浏览0引用
0
0
OA14.05 KRAS G12C Inhibitor IBI351 in Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Pivotal Phase 2 Study
Q. Zhou,X. Meng, L. Sun,D. Huang,N. Yang, Y. Yu, M. Zhao,W. Zhuang, Y. Hu, Y. Pan, M. Sun, J. Shan, R. Guo,Q. Chu, C. Xu, J. Lin, J. Huang, M. Huang, S. Zhang, Y.-L. Wu
Journal of Thoracic Oncologyno. 10 (2024): S42
引用0浏览0引用
0
0
KRAS G12C Inhibitor IBI351 in Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Pivotal Phase 2 Study
Q. Zhou,X. Meng, L. Sun,D. Huang,N. Yang, Y. Yu, M. Zhao,W. Zhuang, Y. Hu, Y. Pan,M. Sun, J. Shan,R. Guo,Q. Chu, C. Xu, J. Lin, J. Huang, M. Huang, S. Zhang, Y. L. Wu
JOURNAL OF THORACIC ONCOLOGYno. 10 (2024): S42-S42
引用0浏览0引用
0
0
Safety and Efficacy of AL2846 Combined with TQB2450 in NSCLC Patients with Previous PD-(L)1 Inhibitor Treated (NCT06116240)
D. Huang,Z. Song, J. Qin,D. Zhong, Y. Chen, W. Huang, G. Li, L. Lin, L. Wang
JOURNAL OF THORACIC ONCOLOGYno. 10 (2024): S396-S396
引用0浏览0引用
0
0
Garsorasib in KRAS G12C-Mutated Non-Small-Cell Lung Cancer: Updated Results from a Phase 2 Study
Z. Li,S. Lu,X. Dang,D. Huang, S. Jin, W. Li,J. Shi, X. Wang, Y. Zhang,Z. Song, J. Zhang,W. Zhuang, X. Liu, L. Jiang,X. Meng,M. Zhao, J. Zhou, L. Zhang, P. Wang, H. Luo, J. Yang,S. Cang, J. Wang,J. Cui,Y. Yu, Z. Zhang, J. Lu, W. Yang, G. Li,J. Feng,D. Lv,L. Wu, Y. Fang, Y. Wang, Y. Zhao, B. Cao, W. Zhu,Z. Zhuang, Q. Li, M. Wang, H. Zhou,X. Dong,S. Hu, J. Fang, C. -W. Xu, W. Wang,Z. Xiang, Z. Shi
JOURNAL OF THORACIC ONCOLOGY（2024）
引用0浏览0引用
0
0
Randomized, Open-Label, Phase III Study of SAF-189s Versus Crizotinib in First-Line ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
A. Xiong, N. Yang,X. Dong, Y. Fan, L. Xu,P. Pan,Y. Yu, J. Zhou, Y. Li,J. Cui, M. Wang, Y. Zhang, R. Chen, H. Niu, H. Qin, S. Guo,D. Huang, H. Wu,W. Yao, Z. Zhang, J. Fang, Y. Fang, M. Li, L. Liu,W. Su, Z. Wu, X. Wang, H. Liu, J. Hu, X. Xiang, C. Zhou
JOURNAL OF THORACIC ONCOLOGYno. 10 (2024): S27-S28
引用0浏览0引用
0
0
P4.11E.03 Safety and Efficacy of AL2846 Combined with TQB2450 in NSCLC Patients with Previous PD-(L)1 Inhibitor Treated (NCT06116240)
D. Huang,Z. Song, J. Qin,D. Zhong, Y. Chen, W. Huang, G. Li, L. Lin, L. Wang
Journal of Thoracic Oncologyno. 10 (2024): S396
引用0浏览0引用
0
0
OA14.03 Garsorasib in KRAS G12C-Mutated Non-Small-Cell Lung Cancer: Updated Results from a Phase 2 Study
Z. Li,S. Lu,X. Dang,D. Huang, S. Jin, W. Li, J. Shi, X. Wang, Y. Zhang, Z. Song, J. Zhang,W. Zhuang, X. Liu, L. Jiang,X. Meng, M. Zhao, J. Zhou, L. Zhang, P. Wang, H. Luo
Journal of Thoracic Oncologyno. 10 (2024): S40-S41
引用0浏览0引用
0
0
加载更多
作者统计

#Papers: 49

#Citation: 56

H-Index: 4

G-Index: 6

Sociability: 5

Diversity: 1

Activity: 6

  • 合作者
  • 学生
  • 导师
暂无相似学者，你可以通过学者研究领域进行搜索筛选
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn